The prevalence of solid tumors and hematologic malignancies among patients with Down Syndrome: A systematic review and meta-analysis
A partir d'une revue systématique de la littérature publiée jusqu'en juillet 2024 (15 études, 62 121 personnes), cette méta-analyse évalue la prévalence globale du cancer chez les personnes atteintes du syndrome de Down
Résumé en anglais
Background: Patients with Down syndrome (DS) have a unique genetic and clinical profile that may increase the risk of cancer.
Methods: A literature search on PubMed, Scopus, Web of Science, and the Cochrane databases was conducted, focusing on studies to investigate the prevalence of solid and hematologic tumors in DS.
Results: Fifteen studies were included, encompassing 62,121 individuals with Down syndrome (DS). The overall prevalence of cancer in DS was 2.02% (95% CI: 1.63% to 2.50%). The analysis of hematological tumors revealed a prevalence of 1.18% (95% CI: 0.86% - 1.62%) for leukemia, 0.86% (95% CI: 0.73% - 1.01%) for acute lymphoblastic leukemia, and 0.51% (95% CI: 0.29% - 0.90%) for acute myeloid leukemia. Among solid tumors, testicular cancer had the highest prevalence, at 0.22% (95% CI: 0.12% - 0.43%).
Conclusions: Our results highlight the need for targeted screening strategies, prevention strategies and treatment protocols among those with Down syndrome.
